• Whole genome-wide profiling
• Measures tumor fraction
• Analyzes copy number variants
• Complementary approach to targeted deep sequencing panels for a broader view of the genomic landscape of tumors
*CLIA-validated assay requires two tubes of 10mL blood
Integrating whole-genome sequencing with targeted deep sequencing panels helps to provide a broader and comprehensive view of the genomic landscape in cancer. The increasing information provided by L-P WGS can be valuable for monitoring treatment response, detecting disease progression early, and identifying emergent clones associated with therapeutic resistance.
Available in RUO and CLIA-validated assay
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.